Rising Diabetes Prevalence Drives Growth in Liraglutide and Semaglutide Markets : Core Growth Enabler in the Liraglutide And Semaglutide Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Liraglutide And Semaglutide Industry Market Size Be by 2025?
In recent times, the liraglutide and semaglutide market has seen quick and impressive growth. The growth is projected to continue, with the market size increasing from $15.19 billion in 2024 to an estimated $16.98 billion in 2025, making for a compound annual growth rate (CAGR) of 11.8%. The motivating factors for such striking growth during the historic phase can be traced back to increased diabetes cases, a rise in diseases related to obesity, more numerous clinical trials, greater investment in research and development focused on diabetes, and the escalating demand for easy-to-use treatment methods.

What's the Long-Term Growth Forecast for the Liraglutide And Semaglutide Market Size Through 2029?
The market size for liraglutide and semaglutide is set to experience significant growth in the future, reaching $26.24 billion in 2029 with a compound yearly growth rate of 11.5%. The anticipated growth during the forecast period can be linked to factors such as greater uptake of GLP-1 receptor agonists, increased health care expenses, expansion of pharmaceutical firms' product offerings, growing disposable income levels, and an increasing aging population with a higher risk of diabetes. Future trends predicted to further stimulate this growth include the incorporation of digital health platforms, application of personalized dosage strategies, advancements in medication delivery technologies, creation of biosimilar versions, and the use of artificial intelligence in treatment decision-making processes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report

What Are the Key Growth Drivers Fueling the Liraglutide And Semaglutide Market Expansion?
A surge in the number of individuals suffering from diabetes is anticipated to boost the growth of the liraglutide and semaglutide markets in the future. Diabetes is a long-term condition marked by higher blood sugar levels due to the body's resistance to insulin and inadequate insulin production. The escalating number of diabetes cases is attributed to inactive lifestyles, poor dietary practices, and genetic factors. Both liraglutide and semaglutide play a critical role in treating diabetic individuals by successfully managing blood glucose levels and minimizing the chances of diabetes-related complications. For example, in June 2024, the National Health Service, a governmental department based in the UK, stated that in 2023, they discovered an additional 549,000 individuals in England at risk of developing type 2 diabetes. This brings the total number of people with non-diabetic hyperglycemia, also known as pre-diabetes and registered with a GP, to 3,615,330. It's a remarkable rise compared to the 3,065,825 individuals in 2022, denoting a nearly 20% increase. Consequently, the escalating number of individuals with diabetes stimulates the growth of the liraglutide and semaglutide markets.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18400&type=smp

What Are the Key Trends Driving Liraglutide And Semaglutide Market Growth?
Leading companies within the liraglutide and semaglutide markets are focusing their efforts on creating anti-diabetic biosimilar medications aimed at optimizing glucose management and lowering cardiovascular threats for those with diabetes. These anti-diabetic biosimilars, which are affordable replicas of original diabetic biologics, are designed to provide the same benefits as their originals. For example, in January 2024, India's Glenmark Pharmaceuticals Ltd. introduced a biosimilar version of the widely used anti-diabetic medication, Liraglutide, marking its first launch in India. This anti-diabetic medication is a biosimilar of Liraglutide, designed to enhance glycemic control in adults suffering from type 2 diabetes mellitus. This introduction paves the way for reduced daily treatment costs, dramatically broadening availability for more patients across the country. Sold at roughly INR 100 for a customary 1.2 mg daily dosage, it leads to approximately 70% reduction in treatment expenses and necessitates a prescription for acquisition.

How Is the Liraglutide And Semaglutide Market Segmented?
The liraglutide and semaglutide market covered in this report is segmented -

1) By Type: Pills, Liquid
2) By Administration: Parenteral, Oral
3) By Application: Type 2 Diabetes Mellitus, Obesity, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Pills: Oral Tablets (Liraglutide, Semaglutide), Extended-Release Oral Formulations
2) By Liquid: Injectable Solutions (Liraglutide, Semaglutide), Pre-Filled Syringes, Vials For Injection

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18400&type=smp

Which Companies Are Leading the Charge in Liraglutide And Semaglutide Market Innovation?
Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

Which Regions Are Leading the Global Liraglutide And Semaglutide Market in Revenue?
North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18400

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.